dc.contributor.author |
Denny, William A |
|
dc.contributor.author |
Flanagan, Jack U |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2022-02-20T22:02:53Z |
|
dc.date.available |
2022-02-20T22:02:53Z |
|
dc.date.issued |
2021-2 |
|
dc.identifier.issn |
1354-3776 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/58276 |
|
dc.description.abstract |
<h4>Introduction</h4>Colony stimulating factor 1 receptor (CSF-1R, also known as c-FMS kinase) is in the class III receptor tyrosine kinase family, along with c-Kit, Flt3 and PDGFRα. CSF-1/CSF-1R signaling promotes the differentiation and survival of myeloid progenitors into populations of monocytes, macrophages, dendritic cells and osteoclasts, as well as microglial cells and also recruits host macrophages to develop into tumor-associated macrophages (TAMs), which promote tumor progression and metastasis.<h4>Areas covered</h4>In the last 5 years, and recently stimulated by the approval of pexidartinib (Turalio™, Daiichi Sankyo) in 2019 for the treatment of tenosynovial giant cell tumors, there has been a large increase in activity (both journal articles and patent applications) around small molecule inhibitors of CSF1R. Features of this work have been the surprising diversity of chemical classes shown to be potent and selective inhibitors, and the breadth of disease states (cancer, arthritis, and 'cytokine storm' syndromes) covered by CSF1R inhibitors. All these aspects are covered in the following sections.<h4>Expert opinion</h4>The field has developed rapidly from 2014 to the present, with many different chemotypes proving to be potent inhibitors. The range of potential utilities of CSF1R inhibitors has also expanded to include dementia, ulcerative colitis/Crohn's disease, rheumatoid arthritis inflammation, and fibrosis. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Informa UK Limited |
|
dc.relation.ispartofseries |
Expert opinion on therapeutic patents |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Animals |
|
dc.subject |
Humans |
|
dc.subject |
Neoplasms |
|
dc.subject |
Neoplasm Metastasis |
|
dc.subject |
Disease Progression |
|
dc.subject |
Receptor, Macrophage Colony-Stimulating Factor |
|
dc.subject |
Protein Kinase Inhibitors |
|
dc.subject |
Patents as Topic |
|
dc.subject |
Tumor-Associated Macrophages |
|
dc.subject |
Alzheimers |
|
dc.subject |
CSF1R |
|
dc.subject |
Colony-stimulating factor-1 receptor |
|
dc.subject |
cancer |
|
dc.subject |
inflammation |
|
dc.subject |
Animals |
|
dc.subject |
Disease Progression |
|
dc.subject |
Humans |
|
dc.subject |
Neoplasm Metastasis |
|
dc.subject |
Neoplasms |
|
dc.subject |
Patents as Topic |
|
dc.subject |
Protein Kinase Inhibitors |
|
dc.subject |
Receptor, Macrophage Colony-Stimulating Factor |
|
dc.subject |
Tumor-Associated Macrophages |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Chemistry, Medicinal |
|
dc.subject |
Pharmacology & Pharmacy |
|
dc.subject |
Colony-stimulating factor-1 receptor |
|
dc.subject |
CSF1R |
|
dc.subject |
cancer |
|
dc.subject |
Alzheimers |
|
dc.subject |
inflammation |
|
dc.subject |
FMS TYROSINE KINASE |
|
dc.subject |
MICROGLIAL PROLIFERATION |
|
dc.subject |
CSF-1R INHIBITOR |
|
dc.subject |
RECEPTOR |
|
dc.subject |
JNJ-40346527 |
|
dc.subject |
0903 Biomedical Engineering |
|
dc.subject |
1115 Pharmacology and Pharmaceutical Sciences |
|
dc.title |
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1080/13543776.2021.1839414 |
|
pubs.issue |
2 |
|
pubs.begin-page |
107 |
|
pubs.volume |
31 |
|
dc.date.updated |
2022-01-10T00:58:11Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/33108917 |
|
pubs.end-page |
117 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
823476 |
|
dc.identifier.eissn |
1744-7674 |
|
pubs.online-publication-date |
2020-10-28 |
|